NeurAegis, Inc.

NeurAegis, Inc is a US-based, late preclinical stage neuropharmaceutical company focused on developing breakthrough treatments for neurological disorders.

We are pioneering the development of first-in-class, novel protease inhibitors, with our initial focus on traumatic brain injury (TBI)/concussion – a significant public health problem affecting millions annually.

NeurAegis distinguishes itself through its commitment to addressing a critical unmet medical need with innovative, targeted therapies, backed by a strong intellectual property portfolio and an experienced leadership team. Our research targets neuronal damage and death following TBI, offering potential for long-term benefits.

We are currently pursuing indications beyond TBI, including epilepsy, and have secured significant grant funding and established strategic partnerships to accelerate our drug development program. Concussion therapy and epilepsy drug market expansion are key strategic goals.